Fluticasone Propionate is a potent, synthetic, trifluorinated glucocorticoid with high topical anti-inflammatory activity. The 0.005% w/v (equivalent to 50 mcg/mL or 0.05 mg/mL) concentration is primarily formulated for topical dermatological use. It acts by binding to glucocorticoid receptors, inhibiting the release of pro-inflammatory mediators, and reducing vasodilation and edema. It is considered a medium-potency topical corticosteroid in the Indian classification system.
Adult: Apply a thin film to the affected area once or twice daily. Frequency should be guided by severity; twice daily is common initially, tapering to once daily or less frequent as condition improves.
Note: 1. Wash and dry the affected area gently. 2. Apply a thin layer (a pea-sized amount for an area the size of 2-3 adult palms) and rub in gently until it disappears. 3. Do not cover with airtight dressings (occlusion) unless specifically directed by a physician, as this increases absorption and side effects. 4. Wash hands after application unless hands are the treated area. 5. Avoid contact with eyes, mouth, nose, and mucous membranes.
Fluticasone propionate is a potent anti-inflammatory and immunosuppressive agent. It diffuses across cell membranes and binds with high affinity to cytoplasmic glucocorticoid receptors. The activated receptor complex translocates to the nucleus, where it modulates gene transcription. It increases the synthesis of anti-inflammatory proteins (like lipocortin-1) and decreases the synthesis of pro-inflammatory mediators.
Pregnancy: Pregnancy Category C (US FDA). Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies show teratogenicity at high systemic doses. Use the minimum effective dose for the shortest duration. Avoid large areas or long-term use.
Driving: No known effects on driving ability.
| Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Clarithromycin) | May inhibit the metabolism of systemically absorbed fluticasone, increasing the risk of systemic corticosteroid side effects and adrenal suppression. | Major |
| Other Topical Corticosteroids | Additive risk of local and systemic side effects. | Major |
| Live Vaccines (e.g., BCG, MMR, Varicella) | Theoretical risk of diminished immune response and potential vaccine-related infection if significant systemic immunosuppression occurs. | Moderate |